Consultant Medical & Hemato oncologist, MOC Malad, Internal medicine, Alumnus Tata memorial hospital (Mumbai), https://teapawt.net/t.co/NFbpW9ThT8
Mumbai, India
Joined May 2016
- Tweets637
- Following91
- Followers172
- Likes1.7K
Rup Jyoti Sarma retweeted
3 practice refinements after #ESMO26:
1. Always offer screening brain MRI at metastatic diagnosis (HER2+/TN) and offer 1L ADCs in case of BM
2. Consider adding tucatinib to HP after local therapy for brain-only PD while on 1L HP maintenance
3. Limit sequential TOPO1 ADCs
Rup Jyoti Sarma retweeted
Cancer should never take away a person’s right to dignified and timely care. Your contribution can help provide patients with the treatment, comfort and support they deserve.
Every rupee counts unitedwaymumbai.org/fundrais…
Real world data of Elacestrant in HR+/Her2- MBC: Take home points:
1. Best outcomes were in patients with 1 prior line of ET+ CDK4/6i given for >12 months- TTNT 12.2 months.
2. Liver mets reduces efficacy: TTNT 6.5months.
2
51
3. Has activity in patients with brain mets also.
4. Coexisting PIK3CA decreases TTNT.
5. ~ 40% has coexisting PIK3CA mutations.
6. Has activity in patients who received prior fulvestrant/ chemo also.
sciencedirect.com/science/ar…
35
Rup Jyoti Sarma retweeted
PERSEUS is the gold standard benchmark outcome for Newly Diagnosed Myeloma
6 year overall survival: 86%
6 year PFS 81%
with quad induction and Dara-Len maintenance.
As we test bispecifics, ADCs, CARTs etc, any new approach should be better. A new therapy CANNOT have even 5% all cause mortality in first 4 years.
There is no room for error with infection related mortality. No early drop off. No learning curve. As a field we have to establish preventive measures to prevent infection related deaths. #IMS26
4/5 dMMR rectal cancer will have Lynch syndrome, but only 1/3 dMMR colon cancer will have Lynch. #OncoTrivia
35
Rup Jyoti Sarma retweeted
The most important part of informed consent in medicine is asking patient to repeat back to you their understanding of why the therapy (or procedure) is being recommend and risks
Equally as important, they should understand expected outcome if they do not proceed with therapy
Finally something to cherish about in PDAC after decades of result.
Presented at #ASCO26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM
@ASCO
ALT Graph from a study published in the New England Journal of Medicine on daraxonrasib versus chemotherapy for metastatic pancreatic cancer. The x-axis represents months, and the y-axis shows the percentage of patients alive. Two lines indicate survival rates: daraxonrasib (blue) and chemotherapy (gray). The bottom section lists patients at risk over time. Title and journal logo are included.
46
Rup Jyoti Sarma retweeted
7yr CROWN update of 1L lorlatinib
55% progression-free at 7 YEARS.
Median PFS STILL not reached.
In metastatic solid tumors, this is essentially unheard of. Let that sink in.
And hopefully, one day, this becomes the standard (or even better) for ALL metastatic cancers.#ASCO26 – at Chicago, IL
Rup Jyoti Sarma retweeted
Proud to share ph III RCT on low-dose abiraterone (250 mg w/food) vs std-dose abi in CRPC.
Despite markedly lower drug exposure, low-dose abi had comparable efficacy, safety & QoL: supporting affordable and practical treatment ascopubs.org/doi/10.1200/GO-…
#ProstateCancer @OncoAlert
Rup Jyoti Sarma retweeted
The results of the recent state elections have been dramatic by any measure.
But for me, this image will remain the most unforgettable outcome of the elections.
More than 166,000 votes were cast between the two leading candidates in this constituency in Tamil Nadu.
And history was changed by just one vote.
This image should be shown in every school in the country & perhaps around the world.
So that every child understands that when they grow up, the greatest power they may possess is the Power of One.
The power of their one vote.
Rup Jyoti Sarma retweeted
Many leaders in medicine are focused on AI and how it’s going to solve problems in medicine. Maybe.
But doctors with great clinical acumen, empathy, and the wisdom to make the right judgment call are the ones we need more of, and who patients want and seek out. This is the important stuff.
The power of precision oncology
Targeted therapies in AML. So many!
FLT3 mutation = gilteritinib, midostaurin, quizartinib
IDH1 mutation = ivosidenib, olutasidenib
IDH2 mutation = enasidenib
KMT2A rearrangement = revumenib
NPM1 mutatuion = revumenib, ziftomenib
CD33 = gemtuzumab ozogamicin
BCL2 = venetoclax
66
Very few instances of accelerated approval of a 1L therapy based on a single arm trial!
Zongertinib now @FDAOncology ✅ (accelerated) approved for Her2 (ERBB2) mutated NSCLC in 1L based off #BeamionLUNG1 (single arm n=72)
- ORR: 76%
- Responders 64% w/ more than 6 months response and 44% w/ more than 12 months of response
- New SoC
#lcsm #LungCancer #OncTwitter
37
The power of precision oncology. We have miles to go..
BRCAAway final OS update.
Front-line combination mattered.
Sequential therapy did not catch up.
Phase 2.
But a clear signal.
Test early.
Treat early.
#gu26 #cancer #oncology
@oncoalert @ASCO @medicalwatchBC
@DrChoueiri @yekeduz_emre @neerajaiims @CParkMD @Silke_Gillessen @PGrivasMDPhD @VivekSubbiah @TwoOncDocs @OncBrothers @Larvol @nataliagandur @montypal @crisbergerot @DrDanielHeng @TiansterZhang @HHammersMD @sonpavde @drenriquegrande @scserendipity1 @tompowles1 @BraunMDPhD @uromigos @MattGalsky @apolo_andrea
@bavilima @SuyogCancer @ONCOassist @gbanna74 @NazliDizman @MedicalwatchFTW @OncLive @urologysummit @IMG_Oncologists @AmandaBinDC @sarah_c_hopkins @MikeSerzanMD
30
Rup Jyoti Sarma retweeted
85 years of care, compassion, and commitment.
Since 1941, @TataMemorial has remained dedicated to accessible cancer care, advancing research, and training the next generation of oncology professionals.
Honouring the legacy. Renewing the commitment.
#85YearsOfCare #FoundationDay
